OptimizeRx Corporation (OPRX)
| Market Cap | 232.94M |
| Revenue (ttm) | 78.21M |
| Net Income (ttm) | -18.07M |
| Shares Out | 18.27M |
| EPS (ttm) | -1.03 |
| PE Ratio | n/a |
| Forward PE | 46.41 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 162,445 |
| Open | 12.87 |
| Previous Close | 12.85 |
| Day's Range | 12.50 - 13.01 |
| 52-Week Range | 6.92 - 16.65 |
| Beta | 1.05 |
| Analysts | Strong Buy |
| Price Target | 16.00 (+26.08%) |
| Earnings Date | May 14, 2024 |
About OPRX
OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real... [Read more]
Financial Performance
In 2023, OptimizeRx's revenue was $71.52 million, an increase of 14.53% compared to the previous year's $62.45 million. Losses were -$17.57 million, 53.6% more than in 2022.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for OPRX stock is "Strong Buy." The 12-month stock price forecast is $16.0, which is an increase of 26.08% from the latest price.
News
OptimizeRx Reports First Quarter 2024 Financial Results
WALTHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and enga...
OptimizeRx to Participate in Upcoming Investor Conferences
WALTHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and eng...
OptimizeRx Provides Business Update and Sets First Quarter 2024 Conference Call for May 14, 2024 at 4:30 p.m. ET
1Q24 revenue expected to grow over 40% year-over-year and come in between $18.5 - $19.2 million First quarter revenue and adjusted EBITDA to come in ahead of consensus DAAP adoption and cross selling ...
OptimizeRx Releases 2024 Environmental, Social, and Governance (ESG) Report
WALTHAM, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and enga...
OptimizeRx Reports Strong Fourth Quarter and Full Year 2023 Financial Results
WALTHAM, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and enga...
OptimizeRx Named America's Fastest-Growing Company for Fifth Year in a Row
WALTHAM, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and enga...
OptimizeRx Sets Fourth Quarter 2023 Conference Call for March 28, 2024 at 8:30 a.m. ET
WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and en...
OptimizeRx Provides an Update on the Timing of Earnings Call and Reaffirms Prior Revenue and Adjusted EBITDA Estimates for FY2023
WALTHAM, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and en...
OptimizeRx Powers Walmart's ‘Specialty Pharmacies of the Community' Outreach Effort
WALTHAM, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and enga...
OptimizeRx Announces Strategic Board Changes to Support Growth and Evolving Landscape
WALTHAM, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engag...
OptimizeRx Preannounces Select Expected 2023 Financials and Provides a Business Update
WALTHAM, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and en...
OptimizeRx to Participate at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco
WALTHAM, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and eng...
OptimizeRx Reports Third Quarter 2023 Financial Results
- Increases guidance for 2023 and introduces guidance for 2024- Total revenue of $16.3 million- GAAP net loss per share of $(0.17)- Non-GAAP net income per share of $0.09- Total DAAP (fka RWD) deals f...
OptimizeRx Announces Completion of Medicx Acquisition and Sets Third Quarter 2023 Conference Call for November 6, 2023, at 8:30 a.m. ET
Executive Leadership expands with Steve Silvestro being promoted to President, and Theresa Greco assuming the role of Chief Commercial Officer Executive Leadership expands with Steve Silvestro being p...
OptimizeRx Announces Agreement to Acquire Medicx Health for $95 million to Expand its Omnichannel Reach to Consumers
Preannounces Preliminary Third Quarter 2023 Results OptimizeRx adds new, proven, profitable technologies to become the most comprehensive healthcare marketing platform in the nation. Consolidated reve...
OptimizeRx Expands AI Powered Omnichannel Platform
WALTHAM, Mass., Aug. 24, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, ...
OptimizeRx Reports Second Quarter 2023 Financial Results
– RWD.AI-enabled portion of the core business sees 186% YOY growth during the first half of 2023 – Non-core business is lagging – Total revenue of $13.8 million – GAAP net loss per share of $(0.24) – ...
OptimizeRx Sets Second Quarter 2023 Conference Call for August 14, 2023 at 4:30 p.m. ET
ROCHESTER, Mich., July 31, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy...
OptimizeRx's CEO Provides 2023 Midyear Strategic Update
ROCHESTER, Mich., May 24, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy,...
OptimizeRx's Karina Castagna Named One of the 2023 PM360 ELITE 100
Castagna was recognized as a Digital Crusader for her ongoing and leading-edge work in digital access to therapies for patients Castagna was recognized as a Digital Crusader for her ongoing and leadin...
OptimizeRx Reports First Quarter 2023 Financial Results
ROCHESTER, Mich., May 10, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy,...
OptimizeRx Releases 2023 Environmental, Social and Governance (ESG) Report
ROCHESTER, Mich., April 04, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therap...
Financial Times Ranks OptimizeRx Amongst The Americas' Fastest Growing Companies for the Fourth Consecutive Year
– AI driven RWD deals grow from 6 completed in 2022 to several dozen in pipeline today, representing the rapid adoption of OptimizeRx's health technology enablement platform services – AI driven RWD d...
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Cara Therapeutics (NASDAQ:CARA), AdaptHealth (NASDAQ:AHCO)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
OptimizeRx Authorizes $15 Million Share Repurchase Program
ROCHESTER, Mich., March 14, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therap...